Search

Displaying results 4451 - 4460 of 10000 in total
  1. Target

    NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12

    go.drugbank.com/bio_entities/BE0000754
    TargetHumans

    Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

    Synonyms: Complex I-B17.2
  2. Target

    Cytochrome P450 2A6

    go.drugbank.com/bio_entities/BE0003336
    TargetEnzymeHumans

    Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide, ifosphamide and tegafur. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase.

    Synonyms: Cytochrome P450(I)
  3. Target

    Phospholipid-transporting ATPase ID

    go.drugbank.com/bio_entities/BE0013936
    TransporterHumans

    Catalytic component of P4-ATPase flippase complex, which catalyzes the hydrolysis of ATP coupled to the transport of phosphatidylcholine (PC) from the outer to the inner leaflet of the plasma membrane. May contribute to the maintenance o...

    Synonyms: ATPase class I type 8B member 2
  4. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    In November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339] … Kanjinti (trastuzumab-anns)[L14135] and Hercessi[L52840] are other biosimilars approved by the FDA. In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved.

    Mixtures: PHESGO® 600MG/600MG, PHESGO® 600MG/600MGCategories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
  5. Drug

    Piperonyl butoxide

    go.drugbank.com/drugs/DB09350
    ApprovedVet approved

    It has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone. … Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist.

    Mixtures: Up and up lice killing maximum strength, R & C Shampoo With ConditionerCategories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors
  6. Drug

    Fluocinolone acetonide

    go.drugbank.com/drugs/DB00591
    ApprovedInvestigationalVet approved

    [T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676] … [T357] It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices.

    Mixtures: OCIDERM-N, CINOLON-NCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  7. Drug

    Xylitol

    go.drugbank.com/drugs/DB11195
    ApprovedInvestigational

    Xylitol is a non-fermentable sugar alcohol by most plaque bacteria, indicating that it cannot be fermented into cariogenic acid end-products [A32423]. … The recommended dose of xylitol for dental caries prevention is 6–10 g/day, and most adults can tolerate 40 g/day without adverse events [A22081].

    Mixtures: Fluor-a-day, Fluor-a-dayCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Bamlanivimab

    go.drugbank.com/drugs/DB15718
    ApprovedInvestigational

    [L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020. … [A224044, L20974] It is set to enter phase 3 clinical trials.

  9. Drug

    Pergolide

    go.drugbank.com/drugs/DB01186
    ApprovedVet approvedWithdrawn

    It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. … The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor AgonistsProducts: PERGOLID-NEURAX 1 MG
  10. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy

    Synonyms: IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMER, IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMERProducts: TYSABRI®, TYSABRI® SUBCUTÁNEO 150MG/ML